Live Breaking News & Updates on Epcoritamab Duobody|Page 4

Stay updated with breaking news from Epcoritamab duobody. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Dr Phillips on the FDA Approval of Epcoritamab in R/R DLBCL

Tycel Phillips, MD, discusses the significance of the FDA approval of the bispecific antibody epcoritamab in patients with relapsed/refractory diffuse large B-cell lymphoma. ....

Tycel Phillips , Department Of Hematology Hematopoietic Cell Transplantation , Division Of Lymphoma , Hematopoietic Cell Transplantation , City Of Hope , Patients With Relapsed Refractory Largeb Cell Lymphoma , Epcore Nhl 1 Trial ,

Genmab A/S: EPKINLY (epcoritamab-bysp) Approved by U.S. Food and Drug Administration as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)

Results from phase 2 clinical trial demonstrated EPKINLY (epcoritamab-bysp) delivered 61 percent overall response rate, 38 percent complete response, and 15.6-month median duration of response in ....

New Jersey , United States , Genmab Duobody , Andrew Carlsen , Marisol Peron , Meghan Gutierrez , Tycel Phillips , Gewinn Nur , Sallesgn Engl , Drug Administration , Abbvie Biotechnology Ltd , Corporate Affairs , Company Announcement , Lymphoma Research Foundation , Ministry Of Health , Global Communications , Division Of Lymphoma , Genmab Us Inc , Exchange Commission , European Medicines Agency , Department Of Hematology Hematopoietic Cell Transplantation , Chief Executive Officer , Important Safety Information , Important Warnings , Hope Associate Professor , Hematology Hematopoietic Cell ,

Dr Phillips on the FDA Approval of Epcoritamab in R/R LBCL

Tycel Phillips, MD, discusses the significance of the FDA approval of the bispecific antibody epcoritamab in patients with relapsed/refractory large B-cell lymphoma. ....

Tycel Phillips , Division Of Lymphoma , Department Of Hematology Hematopoietic Cell Transplantation , Hematopoietic Cell Transplantation , City Of Hope , Patients With Relapsed Refractory Largeb Cell Lymphoma , Epcore Nhl 1 Trial ,

Epcoritamab Approved by FDA to Treat R/R DLBCL

Approval for the T-cell–engaging bispecific antibody came today from the FDA. ....

United States , Tycel Philips , Thomas Hudson , Department Of Hematology Hematopoietic Cell Transplantation , Division Of Lymphoma , Hematopoietic Cell Transplantation , Boxed Warning , Epcoritamab Bysp , Rr Dlbcl , Bispecific Antibody ,

Genmab A/S: Genmab Showcases Data From Robust Development Program Evaluating Epcoritamab (DuoBody-CD3xCD20) in Patients Across a Broad Range of B-Cell Lymphomas at the 64th Annual ASH Meeting

Epcoritamab featured in multiple data disclosures, including four oral presentations Results presented from the phase 1b/2 EPCORE NHL-2 trial of epcoritamab combined with standard salvage ....

United States , New Orleans , New Jersey , David Freundel , Judith Klimovsky , Andrew Carlsen , Exposition Of The American Society Hematology , Product Communications , Macrophage Propertiesj Immunol , Data From The Observational National Lymphocare Study , National Institutes Of Health , Drug Administration , Exchange Commission , Leukaemia Foundation , Development Of Novel Anti , European Medicines Agency , Lymphoma Research Foundation , Annual Meeting , American Society , Executive Vice President , Chief Development Officer , Diffuse Largeb Cell Lymphoma , Follicular Lymphoma , Biologics License Application , Priority Review , Marketing Authorization Application ,